Glycomet is a brand-name medication that contains metformin as its sole active ingredient. Metformin belongs to the biguanide class of oral antidiabetic agents and is used worldwide for the management of type 2 diabetes mellitus. In Hong Kong, Glycomet is available only by prescription and is supplied as a 500 mg oral pill. The product is regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance. While the specific manufacturer of Glycomet is not disclosed here, the formulation follows the same quality standards required for all prescription medicines marketed in Hong Kong.
Metformin improves blood-glucose control through several complementary actions:
These mechanisms together lower fasting plasma glucose and improve overall glycaemic control without stimulating the pancreas to release more insulin. Metformin’s effect becomes apparent within a few days, reaches a steady state after about two weeks, and its glucose-lowering action persists for the duration of therapy.
In Hong Kong, Glycomet is approved for the treatment of type 2 diabetes mellitus in adult patients. It may be used as monotherapy or in combination with other glucose-lowering agents such as sulfonylureas, DPP-4 inhibitors, or insulin when additional control is required. The medication is intended for patients whose diabetes is not adequately managed by diet and exercise alone.
Metformin is sometimes prescribed for conditions that are not covered by the official label.
Disclaimer: Off-label use requires medical supervision and an individualized risk assessment. These applications have not received formal regulatory approval in Hong Kong.
If any of these conditions apply, a healthcare professional should assess suitability before initiating therapy.
Patients should disclose all prescription medicines, over-the-counter drugs, herbal supplements, and dietary habits to their prescriber before starting Glycomet.
Regular follow-up enables timely dose optimisation and early detection of adverse effects.
This article provides educational information about Glycomet and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Metformin is generally safe for patients with stable cardiovascular disease and may even provide modest cardioprotective benefits. However, clinicians will review individual cardiac status and concomitant medicines before prescribing.
Some studies have shown modest reductions in LDL cholesterol and triglycerides with metformin therapy, but it is not a primary lipid-lowering agent. Patients requiring cholesterol control should continue appropriate lipid-lowering medications.
Metformin does not directly influence blood pressure. Routine monitoring remains important for overall diabetes management, especially because hypertension often co-exists with type 2 diabetes.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be prepared to present it at customs if requested. Avoid storing the pills in extreme heat or humidity during travel.
Formulations can vary by market, which may affect tablet colour, size, or excipients such as lactose or microcrystalline cellulose. Patients with specific allergies should review the local product leaflet.
Stability beyond the printed expiry date is not guaranteed. Using expired medication may result in reduced efficacy or unknown safety, so it should be discarded.
Metformin is primarily eliminated unchanged by the kidneys, not the liver. Mild hepatic impairment does not usually contraindicate its use, but clinicians will assess overall liver function and potential for lactic acidosis.
A high-protein diet does not interfere with metformin’s absorption or action. Patients should maintain consistent meal patterns to help minimise gastrointestinal side effects.
Persistent diarrhoea may indicate intolerance. Patients should contact their healthcare provider, who may recommend dose reduction, gradual titration, or switching to an extended-release formulation if available.
Athletes should monitor blood glucose closely, especially during intense training or competition, as exercise can enhance metformin’s glucose-lowering effect. Hydration and carbohydrate intake should be planned to avoid hypoglycaemia.
